PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 59 | 4 | 661-667
Article title

Ischemia-modified albumin (IMA) is increased in patients with chronic hepatitis C infection and related to markers of oxidative stress and inflammation

Content
Title variants
Languages of publication
EN
Abstracts
EN
Inflammation and oxidative stress have been reported in patients with chronic hepatitis C (CHC) infection, but their influence on ischemia-modified albumin (IMA) levels and diabetes prevalence remains unknown. Sixty-three CHC patients, 28 with diabetes, and 40 healthy controls were enrolled in the study. Circulating levels of oxidative stress markers [Nε-(carboxymethyl)lysine- advanced glycation end products (CML-AGEs) and advanced oxidation protein products-(AOPPs)], pro-inflammatory cytokines (interleukin-6, and tumor necrosis factor α), and high-sensitivity C-reactive protein (hsCRP) were assessed. Compared with the controls, the CHC patients with diabetes showed a significant increase in plasma concentrations of IMA, AOPPs, interleukin-6 and hsCRP (P < 0.05). The values of IMA and hsCRP were more elevated in patients with diabetes than without diabetes (both P < 0.01). The positive relationships were found between hsCRP and presence of diabetes, IMA (both P < 0.01) and AOPP levels (P < 0.05). CML-AGEs did not show any significant correlation with IMA, markers of inflammation and presence of diabetes. In conclusion, we have documented significant elevation in plasma levels of IMA and AOPPs in CHC patients. In addition, circulating IMA was associated with inflammation markers and diabetes prevalence. This observation suggests a relationship between IMA and inflammation in CHC patients with diabetes, which may represent one of the mechanisms involved in the accelerated atherosclerosis in this population.
Year
Volume
59
Issue
4
Pages
661-667
Physical description
Dates
published
2012
received
2012-07-17
revised
2012-11-07
accepted
2012-11-27
(unknown)
2012-12-06
References
  • Bar-Or D, Curtis G, Rao N, Bampos N, Lau E (2001) Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 268: 42-47.
  • Bar-Or D, Lau E, Winkler JV (2000) A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 19: 311-315.
  • Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, Honda SA, Rios CN, Sugiyama CE, Ha CE (2003) Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 49: 581-585.
  • Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ (2010) C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 31: 2087-2091.
  • Castoldi G, Galimberti S, Riva C, Papagna R, Querci F, Casati M, Zerbini G, Caccianiga G, Ferrarese C, Baldoni M, Valsecchi MG, Stella A (2007) Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes. Clin Sci (Lond) 113: 103-108.
  • Ceciliani F, Giordano A, Spagnolo V (2002) The systemic reaction during inflammation: the acute-phase proteins. Protein Pept Lett 9: 211-223.
  • Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S (2010) An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 17: 1-11.
  • Chen CY, Tsai WL, Lin PJ, Shiesh SC (2011) The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease. Clin Chem Lab Med 49: 1817-1821.
  • Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S (2010) An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 17: 1-11.
  • Douglas MW, George J (2009) Molecular mechanisms of insulin resistance in chronic hepatitis C. World J Gastroenterol. 15: 4356-4364.
  • Duarte MM, Rocha JB, Moresco RN, Duarte T, Da Cruz IB, Loro VL, Schetinger MR (2009) Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 42: 666-671.
  • Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072.
  • Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8.
  • Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R (2006) Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts). Clin Ter 157: 457-468.
  • Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D, Zhang X (2008) Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10: 1699-1712.
  • Kaefer M, Piva SJ, De Carvalho JA, Da Silva DB, Becker AM, Coelho AC, Duarte MM, Moresco RN (2010) Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 43: 450-454.
  • Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J (2005) Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res 579: 37-46.
  • Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, Fujita H, Awano K, Kobayashi K, Azumi H, Ejiri J, Hirata K, Kawashima S, Hayashi Y, Yokozaki H, Itoh H, Yokoyama M (2003) Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 23: 1398-1404.
  • Ma SG, Wei CL, Hong B, Yu WN (2011) Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease. Clinics (Sao Paulo) 66: 1677-1680.
  • Ma SG, Jin Y, Hu W, Bai F, Xu W, Yu WN (2012) Evaluation of ischemia-modified albumin and C-reactive protein in type 2 diabetics with and without ketosis. Biomark Insights 7: 19-26.
  • Mastella AK, Moresco RN, da Silva DB, Becker AM, Duarte MM, Giovelli LL, da Silva SH, Rossato L, Moretto MB, da Silva JE (2009) Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. Biomed Pharmacother 63: 762-766.
  • Negi SI, Pankow JS, Fernstrom K, Hoogeveen RC, Zhu N, Couper D, Schmidt MI, Duncan BB, Ballantyne CM (2012) Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the atherosclerosis risk in communities study. Diabetes Care 35: 1513-1518.
  • Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T (2009) Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 80: 306-310.
  • Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P (2001) Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol 35: 279-283.
  • Piwowar A, Knapik-Kordecka M, Warwas M (2008) Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis Markers 24: 311-317.
  • Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, Ding FH, Chen QJ, Lou S, Shen J, Fang DH, Shen WF (2006) Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 5: 27.
  • Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V (2008) Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 49: 260-266.
  • Sbarouni E, Georgiadou P, Voudris V (2011) Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 49: 177-184.
  • Valle Gottlieb MG, da Cruz IB, Duarte MM, Moresco RN, Wiehe M, Schwanke H, Bodanese LC (2010) Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 95: 586-591.
  • Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313.
  • Yu Q, Li Y, Wang Y, Zhao S, Yang P, Chen Y, Fan J, Liu E (2012) C-reactive protein levels are associated with the progression of atherosclerotic lesions in rabbits. Histol Histopathol 27: 529-535.
  • Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M (2009) Elevated advanced oxidation protein products levels in patients with liver cirrhosis. Acta Biochim Pol 56: 679-685.
  • Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M (2011) Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between alcohol-related and HCV-related cirrhosis. Acta Biochim Pol 58: 59-65.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv59p661kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.